Pheochromocytoma other diagnostic studies: Difference between revisions
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}} | {{CMG}} | ||
Please help WikiDoc by adding more content here. It's easy! Click [[Help:How_to_Edit_a_Page|here]] to learn about editing. | |||
==Overview== | ==Overview== | ||
==Other Diagnostic Studies== | ==Other Diagnostic Studies== | ||
| Line 11: | Line 12: | ||
[[Category:Endocrinology]] | [[Category:Endocrinology]] | ||
[[Category:Oncology]] | [[Category:Oncology]] | ||
[[Category:Needs content]] | |||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
Revision as of 17:55, 11 September 2012
|
Pheochromocytoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Pheochromocytoma other diagnostic studies On the Web |
|
American Roentgen Ray Society Images of Pheochromocytoma other diagnostic studies |
|
Risk calculators and risk factors for Pheochromocytoma other diagnostic studies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.
Overview
Other Diagnostic Studies
One diagnostic test used in the past for a pheochromocytoma is to administer clonidine, a centrally-acting alpha-2 agonist used to treat high blood pressure. Clonidine mimics catecholamines in the brain, causing it to reduce the activity of the sympathetic nerves controlling the adrenal medulla. A healthy adrenal medulla will respond to the Clonidine suppression test by reducing catecholamine production; the lack of a response is evidence of pheochromocytoma.